Malaria: Difference between revisions
From WikiDemocracy
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 239: | Line 239: | ||
[https://www.path.org/p/the-worlds-first-malaria-vaccine-what-next/ by PATH] | [https://www.path.org/p/the-worlds-first-malaria-vaccine-what-next/ by PATH] | ||
In 2021, the World Health Organization (WHO) recommended the RTS,S vaccine against malaria for broader use. Two months later, the Gavi Board approved funding to support malaria vaccine roll-out in sub-Saharan Africa. Not only is this the first malaria vaccine to earn such a recommendation and support, but it’s also the world’s first vaccine against a parasite. | In 2021, the World Health Organization (WHO) recommended the RTS,S vaccine against malaria for broader use. Two months later, the Gavi Board approved funding to support malaria vaccine roll-out in sub-Saharan Africa. Not only is this the first malaria vaccine to earn such a recommendation and support, but it’s also the world’s first vaccine against a parasite. | ||
=====Malaria vaccines: the 60-year journey of hope and final success—lessons learned and future prospects===== | |||
[https://tropmedhealth.biomedcentral.com/articles/10.1186/s41182-023-00516-w by Amal A. El-Moamly 17/5/23 BMC] | |||
This review highlights the history of development, and the different approaches and types of malaria vaccines, and the literature to date. It covers the developmental stages of RTS,S/AS01 and recommends steps for its deployment. The review explores other potential vaccine candidates and their status, and suggests options for their further development. It also recommends future roles for vaccines in eradicating malaria. Questions remain on how RTS,S vaccine will work in widespread use and how it can best be utilized to benefit vulnerable communities. | |||
